As Ligand Pharmaceuticals Incorporated (LGND) Shares Rose, Shareholder Knott David M Decreased by $4.78 Million Its Stake

May 17, 2018 - By Darrell Taylor

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Corporate LogoBig Money Sentiment decreased to 1.25 in Q4 2017. It has change of 0.44, from 2017Q3’s 1.69. The ratio is negative due to LGND positioning: 21 sold and 86 reduced. 31 funds bought positions and 103 increased positions. Investors holded 22.76 million in 2017Q3 but now own 22.68 million shares or 0.37% less. Lyon Street Cap Ltd Liability Corp invested in 39,756 shs or 1.82% of the stock. Willingdon Wealth holds 15,075 shs. Etrade Capital Mgmt Limited Liability invested in 0.04% or 9,332 shs. Knott David M holds 41.55% of its capital in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 762,944 shs. 47,662 were accumulated by Matarin Cap Limited Liability. The Sweden-based Nordea Investment Mgmt has invested 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Stratos Wealth Partners owns 44 shs or 0% of their US capital. Assetmark Incorporated, a California-based fund reported 1,056 shs. Huntington National Bank owns 383 shs for 0% of their capital. Ashford Management accumulated 127,987 shs or 2.73% of the stock. Cornerstone Management Ltd Co accumulated 9,413 shs. Colorado-based Elk Creek Limited Liability Corporation has invested 1.08% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Arizona-based Arizona State Retirement Sys has invested 0.05% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Creative Planning invested in 9,483 shs or 0.01% of the stock. Alps has invested 0.02% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND).

LGND had 14 selling transactions and 0 insider purchases since December 20, 2017. This’s net activity of $20.00 million. FOEHR MATTHEW W sold $1.49 million worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) or 8,881 shs on Thursday, May 10. Sabba Stephen L also sold $112,414 worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Monday, March 12. Another trade for 2,500 shs valued at $362,500 was made by KOZARICH JOHN W on Wednesday, January 10. 22,500 shs valued at $3.71 million were sold by HIGGINS JOHN L on Wednesday, January 24. LAMATTINA JOHN L had sold 3,335 shs worth $536,604. $2.62M worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shs were sold by Davis Todd C.

In 2017Q4 Securities and Exchange filling is reported Knott David M’s stake in Ligand Pharmaceuticals Incorporated (LGND) which was reduced by 4.4%. The company’s stock rose 20.51% while stock markets declined as Knott David M sold 35,156 shares. At the end of 2017Q4, the institutional investor held 762,944 shares of the major pharmaceuticals company, valued at $104.47 million, down from 798,100 at the end of the previous reported quarter. $4.12B is the MC of Ligand Pharmaceuticals Incorporated. LGND is reaching $193.19 during the last trading session, after increased 4.22%.Ligand Pharmaceuticals Incorporated is uptrending after having risen 53.11% since May 17, 2017. LGND has 590,205 volume or 83.03% up from normal. LGND outperformed by 41.56% the S&P 500.

For a total of shares it increased its holding in by shares in the quarter, and has risen its stake in .

On August, 6 is anticipated Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)’s earnings report, Zacks reports. This year’s earnings per share analyst estimate is anticipated to be $0.82. That is 51.85 % up compareed to $0.54 earnings per share for last year. If the current earnings per share of $0.82 is accurate, LGND’s profit could be $17.47M. After $1.38 EPS report previous quarter, Wall Street now forecasts -40.58 % negative EPS growth of Ligand Pharmaceuticals Incorporated.

For more Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) news published briefly go to:,,, or The titles are as follows: “Ligand Pharma (LGND) Tops Q1 EPS by 40c” published on May 08, 2018, “Lakewood Capital Notes New Longs in DWS Group, Hyundai and WestRock (WRK); New Shorts in Ligand Pharma …” on April 25, 2018, “Ligand Pharma (LGND) PT Raised to $119 at Deutsche Bank” with a publish date: May 09, 2018, “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” and the last “Lakewood Capital Sees 50% Downside in Ligand Pharma (LGND)” with publication date: April 24, 2018.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Ratings Coverage

In total 5 analysts cover Ligand Pharmaceuticals (NASDAQ:LGND). “Buy” rating has 4, “Sell” are 1, while 0 are “Hold”. 80% are bullish. With $200.0 highest and $162.0 lowest price target Ligand Pharmaceuticals has $163.80 average price target or -15.21% below the current ($193.19) price. 7 are the (NASDAQ:LGND)’s analyst reports since November 20, 2017 according to StockzIntelligence Inc. On Monday, February 26 the firm has “Buy” rating by Roth Capital given. On Thursday, February 22 the firm earned “Buy” rating by Craig Hallum. On Wednesday, March 7 H.C. Wainwright maintained Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) with “Buy” rating. On Thursday, February 22 the stock has “Buy” rating by Stephens. On Wednesday, January 24 the stock has “Buy” rating by H.C. Wainwright. On Monday, November 20 the rating was downgraded by Deutsche Bank to “Sell”. On Wednesday, March 7 the firm has “Buy” rating by Craig Hallum given.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: